ArticleJournal of perinatology : official journal of the California Perinatal Association2005
Experience with caspofungin in the treatment of persistent fungemia in neonates.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Antifungal therapy in children: an update.European journal of pediatrics · 2013Pooled it
- Antifungal therapy for newborn infants with invasive fungal infection.The Cochrane database of systematic reviews · 2012Pooled it
- Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2024Review
- Recent Challenges in Diagnosis and Treatment of Invasive Candidiasis in Neonates.Children (Basel, Switzerland) · 2024Review
- Candidemia in Brazilian neonatal intensive care units: risk factors, epidemiology, and antifungal resistance.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Antifungal Combinations againstJournal of fungi (Basel, Switzerland) · 2022Review
- Antifungal Drugs for Invasive Candida Infections (ICI) in Neonates: Future Perspectives.Frontiers in pediatrics · 2019Review
- Advances in the treatment of invasive neonatal candidiasis.Expert opinion on pharmacotherapy · 2015Review
- Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.Drugs · 2014Review
- Antifungal agents in current pediatric practice.Current infectious disease reports · 2013Article
- Neonatal intensive care unit candidemia: epidemiology, risk factors, outcome, and critical review of published case series.Mycopathologia · 2012Article
- The use of antifungal therapy in neonatal intensive care.Clinics in perinatology · 2012Review
- Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients.Pediatric reports · 2012Article
- Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.Clinical medicine insights. Pediatrics · 2012Article
- Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis.Antimicrobial agents and chemotherapy · 2011Article
- Review
- Use of Antifungal Combination Therapy: Agents, Order, and Timing.Current fungal infection reports · 2010Article
- Echinocandins: A ray of hope in antifungal drug therapy.Indian journal of pharmacology · 2010Article
- Pediatric antifungal agents.Current opinion in infectious diseases · 2009Review
- Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.Journal of perinatology : official journal of the California Perinatal Association · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review our experience of caspofungin in the treatment of persistent candidemia in the neonatal intensive care unit. STUDY
designThis was a retrospective chart review on 13 infants in whom caspofungin was added to conventional antifungals (amphotericin B and/or fluconazole or flucytosine) for the treatment of refractory candidemia.
resultsA total of 12 infants were preterm (gestational age, 24 to 28 weeks) and one was term; the median birth weight was 800 g (range, 530 to 5600 g). Candidemia (Candida albicans in five, C. parapsilosis in six, C. albicans and C. parapsilosis in one and C. tropicalis in one) persisted despite 6 to 30 days of conventional antifungal therapy. After the addition of caspofungin, sterilization of blood cultures was achieved in 11 infants at the median time of 3 days (range, 1 to 21 days). Adverse events included thrombophlebitis (one patient), hypokalemia (two patients) and elevation of liver enzymes (four patients). Three infants had a second episode of candidemia and seven patients died.
conclusionCaspofungin may be an efficacious addition for treatment of candidemia refractory to conventional antifungal therapy. This drug should be further investigated in neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.